Campral Related Published Studies
Well-designed clinical trials related to Campral (Acamprosate)
Predicting the effect of naltrexone and acamprosate in alcohol-dependent patients using genetic indicators. [2009.07]
The effects of acamprosate on alcohol-cue reactivity and alcohol priming in dependent patients: a randomized controlled trial. [2009.07]
Initiating acamprosate within-detoxification versus post-detoxification in the treatment of alcohol dependence. [2009.06]
Searching for responders to acamprosate and naltrexone in alcoholism treatment: rationale and design of the PREDICT study. [2009.04]
Do acamprosate or naltrexone have an effect on daily drinking by reducing craving for alcohol? [2008.06]
Naltrexone versus acamprosate in the treatment of alcohol dependence: A multi-centre, randomized, double-blind, placebo-controlled trial. [2006.10]
Effects of acamprosate on sleep during alcohol withdrawal: A double-blind placebo-controlled polysomnographic study in alcohol-dependent subjects. [2006.09]
A pilot study of oxcarbazepine versus acamprosate in alcohol-dependent patients. [2006.04]
Tinnitus treatment with acamprosate: double-blind study. [2005.09]
Effect of community nurse follow-up when treating alcohol dependence with acamprosate. [2005.07]
A pragmatic trial of acamprosate in the treatment of alcohol dependence in primary care. [2004.11]
A comparison of two intensities of psychosocial intervention for alcohol dependent patients treated with acamprosate. [2004.05]
Acamprosate in alcohol dependence: a randomized controlled efficacy study in a standard clinical setting. [2004.01]
Pharmacodynamic effects of acamprosate on markers of cerebral function in alcohol-dependent subjects administered as pretreatment and during alcohol abstinence. [2004]
Efficacy of acamprosate in the treatment of alcohol-dependent outpatients. [2003.09]
Dose-ranging kinetics and behavioral pharmacology of naltrexone and acamprosate, both alone and combined, in alcohol-dependent subjects. [2003.06]
Acamprosate and its efficacy in treating alcohol dependent adolescents. [2003.06]
Acamprosate in Korean alcohol-dependent patients: a multi-centre, randomized, double-blind, placebo-controlled study. [2003.03]
Comparing and combining naltrexone and acamprosate in relapse prevention of alcoholism: a double-blind, placebo-controlled study. [2003.01]
A pharmacokinetic and pharmacodynamic drug interaction study of acamprosate and naltrexone. [2002.10]
Does psychosocial treatment enhance the efficacy of acamprosate in patients with alcohol problems? [2002.07]
Use of acamprosate and different kinds of psychosocial support in relapse prevention of alcoholism. Results from a non-blind, multicentre study. [2002]
Naltrexone versus acamprosate: one year follow-up of alcohol dependence treatment. [2001.09]
Acamprosate during and after acute alcohol withdrawal: a double-blind placebo-controlled study in Spain. [2001.09]
Acamprosate and relapse prevention in the treatment of alcohol dependence: a placebo-controlled study. [2000.03]
United Kingdom Multicentre Acamprosate Study (UKMAS): a 6-month prospective study of acamprosate versus placebo in preventing relapse after withdrawal from alcohol. [2000.03]
Acamprosate reduces motor cortex excitability determined by transcranial magnetic stimulation. [2000]
Effects of acamprosate on memory in healthy young subjects. [1999.03]
Central effects of acamprosate: part 2. Acamprosate modifies the brain in-vivo proton magnetic resonance spectrum in healthy young male volunteers. [1998.05.20]
Lack of psychotomimetic or impairing effects on psychomotor performance of acamprosate. [1998.05]
Combined efficacy of acamprosate and disulfiram in the treatment of alcoholism: a controlled study. [1998.05]
Acamprosate treatment in a long-term community-based alcohol rehabilitation programme. [1997.11]
Efficacy and safety of acamprosate in the treatment of detoxified alcohol-dependent patients. A 90-day placebo-controlled dose-finding study. [1997.07]
Relapse prevention by acamprosate. Results from a placebo-controlled study on alcohol dependence. [1996.08]
Comparison of acamprosate and placebo in long-term treatment of alcohol dependence. [1996.05.25]
[Does acamprosate diminish the appetite for alcohol in weaned alcoholics?] [1996.03]
Double-blind randomized multicentre trial of acamprosate in maintaining abstinence from alcohol. [1995.03]
Acamprosate: a new pharmacotherapeutic approach to relapse prevention in alcoholism--preliminary data. [1994]
[Acamprosate--a stabilizing factor in long-term withdrawal of alcoholic patients] [1993.03]
[Effect of acute administration of acamprosate on the risk of encephalopathy and on arterial pressure in patients with alcoholic cirrhosis] [1992]
Acamprosate appears to decrease alcohol intake in weaned alcoholics. [1990]
Well-designed clinical trials possibly related to Campral (Acamprosate)
Alcohol treatment effects on secondary nondrinking outcomes and quality of life: the COMBINE study. [2009.03]
Do patients with alcohol dependence respond to placebo? Results from the COMBINE Study. [2008.11]
Effectiveness of sequential combined treatment in comparison with treatment as usual in preventing relapse in alcohol dependence. [2008.11]
Do Patients With Alcohol Dependence Respond to Placebo? Results From the COMBINE Study. [2008.10]
Cost and cost-effectiveness of the COMBINE study in alcohol-dependent patients. [2008.10]
An intervention for treating alcohol dependence: relating elements of Medical Management to patient outcomes with implications for primary care. [2008.09]
An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study. [2008.02]
Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (The COMBINE Study): Examination of Posttreatment Drinking Outcomes. [2008.01]
Psychometrics of the Drinker Inventory of Consequences (DrInC). [2007.08]
Results from two pharmacotherapy trials show alcoholic smokers were more severely alcohol dependent but less prone to relapse than alcoholic non-smokers. [2007.05]
Measuring economic outcomes of alcohol treatment using the economic form 90*. [2007.03]
Hypothalamic-pituitary-adrenocortical axis activity: a target of pharmacological anticraving treatment? [2006.07.01]
Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. [2006.05.03]
The efficacy of compliance therapy in pharmacotherapy for alcohol dependence: a randomized controlled trial. [2005.11]
Increasing leptin precedes craving and relapse during pharmacological abstinence maintenance treatment of alcoholism. [2005.09]
Pharmacological relapse prevention of alcoholism: clinical predictors of outcome. [2005]
Pharmacological treatment of alcohol dependence: a review of the evidence. [1999.04.14]
Other research related to Campral (Acamprosate)
The effect of acamprosate on alcohol craving and correlation with hypothalamic pituitary adrenal (HPA) axis hormones and beta-endorphin. [2009.09.30]
Searching for Responders to Acamprosate and Naltrexone in Alcoholism Treatment: Rationale and Design of the Predict Study. [2009.01.17]
Acute effects of acamprosate and MPEP on ethanol Drinking-in-the-Dark in male C57BL/6J mice. [2008.11]
Acamprosate attenuates the handling induced convulsions during alcohol withdrawal in Swiss Webster mice. [2008.09.03]
Metabotropic glutamate receptor 5 (mGluR5) regulation of ethanol sedation, dependence and consumption: relationship to acamprosate actions. [2008.09]
Acamprosate: recent findings and future research directions. [2008.07]
Investigation of the relationship between in vitro and in vivo release behaviors of acamprosate from enteric-coated tablets. [2008.06]
The effect of acamprosate on alcohol and food craving in patients with alcohol dependence. [2008.03.01]
A microdialysis study of extracellular levels of acamprosate and naltrexone in the rat brain following acute and repeated administration. [2008.03]
Effect of chronic acamprosate treatment on voluntary alcohol intake and beta-endorphin plasma levels in rats selectively bred for high alcohol preference. [2008.02.06]
A randomized, multicentre, open-label, comparative trial of disulfiram, naltrexone and acamprosate in the treatment of alcohol dependence. [2008.01]
Acamprosate efficacy in alcohol-dependent patients: summary of results from three pivotal trials. [2008.01]
Acamprosate supports abstinence, naltrexone prevents excessive drinking: evidence from a meta-analysis with unreported outcomes. [2008.01]
The efficacy of acamprosate and naltrexone in the treatment of alcohol dependence: a relative benefits analysis of randomized controlled trials. [2008]
Acamprosate attenuates cocaine- and cue-induced reinstatement of cocaine-seeking behavior in rats. [2007.12]
Acamprosate in the treatment of alcohol dependence: clinical and economic considerations. [2007.11]
The effect of naltrexone and acamprosate on cue-induced craving, autonomic nervous system and neuroendocrine reactions to alcohol-related cues in alcoholics. [2007.07]
Acamprosate and primitive reflexes. [2007.04]
The effect of naltrexone and acamprosate on cue-induced craving, autonomic nervous system and neuroendocrine reactions to alcohol-related cues in alcoholics. [2007.03.20]
Consideration of acamprosate for treatment of amyotrophic lateral sclerosis. [2007]
Treatment of tinnitus with acamprosate. [2007]
Which treatment for alcohol dependence: naltrexone, acamprosate and/or behavioural intervention? [2006.10]
Evidence of a flip-flop phenomenon in acamprosate pharmacokinetics: an in vivo study in rats. [2006.10]
Effect of oral acamprosate on abstinence in patients with alcohol dependence in a double-blind, placebo-controlled trial: the role of patient motivation. [2006.08]
Combined acamprosate and naltrexone, with cognitive behavioural therapy is superior to either medication alone for alcohol abstinence: a single centres' experience with pharmacotherapy. [2006.05]
Is acamprosate use in alcohol dependence treatment reflected in improved subjective health status outcomes beyond cognitive behavioural therapy alone?. [2006]
Changes in the beta-endorphin plasma level after repeated treatment with acamprosate in rats selectively bred for high and low alcohol preference. [2005.11.04]
An open randomized study comparing disulfiram and acamprosate in the treatment of alcohol dependence. [2005.11]
Acamprosate in the treatment of alcohol dependence. [2005.10]
Production of reactive oxygen species following acute ethanol or acetaldehyde and its reduction by acamprosate in chronically alcoholized rats. [2005.09.27]
A critical review of pharmacoeconomic studies of acamprosate. [2005.09]
The acute anti-craving effect of acamprosate in alcohol-preferring rats is associated with modulation of the mesolimbic dopamine system. [2005.09]
Rationale for combining acamprosate and naltrexone for treating alcohol dependence. [2005.07]
Clinical characterization of use of acamprosate and naltrexone: data from an addiction center in India. [2005.07]
Acamprosate for the treatment of alcohol dependence. [2005.06]
The effects of acamprosate and neramexane on cue-induced reinstatement of ethanol-seeking behavior in rat. [2005.06]
Predictors of acamprosate efficacy: results from a pooled analysis of seven European trials including 1485 alcohol-dependent patients. [2005.03]
Effect of acamprosate on neonatal excitotoxic cortical lesions in in utero alcohol-exposed hamsters. [2005.02.10]
Neuroprotective and abstinence-promoting effects of acamprosate: elucidating the mechanism of action. [2005]
Acamprosate: a review of its use in the maintenance of abstinence in patients with alcohol dependence. [2005]
Combined therapy: what does acamprosate and naltrexone combination tell us? [2004.11]
Alcohol effects during acamprosate treatment: a dose-response study in humans. [2004.07]
Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence: a systematic review. [2004.07]
|
